Agnes Aghetti

Agnes Aghetti

Auto-generated profile, based on publicly available information

Agnes Aghetti

Lariboisière Hospital, AP‐HP

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Brain and Behavior
Verified
Journal Article
Open access
DDDiana Doukhi
Diana Doukhi
VSVirginie Siguret
Virginie Siguret
DVDominique Vodovar
Dominique Vodovar
MDMaxime Delrue
Maxime Delrue
PRPeggy Reiner
Peggy Reiner
ICIsabelle Crassard
Isabelle Crassard
Background: Cerebral venous thrombosis (CVT) has various risk factors, including contraception, pregnancy, neoplasia, and thrombophilia. Nitrous oxide (N₂O), historically used as an anesthetic and more recently as a recreational drug, has been associated with neurological complications such as myeloneuropathy and thromboembolic events. Here, we report two cases of CVT associated with N₂O use and provide a review of the literature on this association.Methods: We describe two local cases of CVT associated with N2O use and 10 additional cases identified by literature review.Results: Among the 12 patients, seven had co‐existing CVT risk factors. Most patients reported chronic N2O use. Hyperhomocysteinemia was reported in nine patients. Management included anticoagulation, vitamin supplementation, cessation of N₂O use, and support for addiction or psychiatric care. The outcome was generally favorable, although one local case experienced CVT recurrence following a relapse in N₂O use.Conclusions: These cases highlight an emerging association between CVT and N₂O use. Prompt recognition of this link is critical to recommend cessation of N₂O use, alongside anticoagulation therapy and consideration of vitamin supplementation to prevent complications and recurrence.

17 March 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
DDDiana Doukhi
Diana Doukhi
AAAgnes Aghetti
Agnes Aghetti
VSVirginie Siguret
Virginie Siguret
JLJulien Labreuche
Julien Labreuche
MDMaxime Delrue
Maxime Delrue
ICIsabelle Crassard
Isabelle Crassard
Background: Anemia has emerged as a risk factor for cerebral venous thrombosis (CVT) and has been associated with poorer outcomes. A specific association has been observed with microcytic anemia, most commonly caused by iron deficiency anemia (IDA). However, detailed data on the clinical, radiological, and therapeutic profile of CVT in patients with IDA remain limited. Methods: We analyzed consecutive patients with CVT and moderate or severe IDA from the prospective Lariboisière Hospital cohort with CVT (1998–2023). Patients with other types of anemia were excluded. Clinical, neuroimaging, treatment, and outcome data were compared with those of patients with CVT without anemia. Results: Among 616 patients with CVT, 64 (10.4%) had moderate or severe IDA. Most were women (96.9%), with chronic gynecological bleeding (eg, fibroids, adenomyosis) as the predominant cause. All received anticoagulation. Additional treatments included iron supplementation, blood transfusion, gynecological surgery, and gonadotropin‐releasing hormone analogs. Compared with patients without anemia (n=502), those with IDA more frequently presented with focal neurological deficits and parenchymal lesions (54.7% versus 35.3%, P =0.0025), particularly venous infarctions (32.8% versus 14.5%, P =0.0002). Despite more severe initial presentations, 1‐year functional outcomes did not significantly differ between groups (adjusted odds ratio for excellent outcome associated with IDA, 0.60 [95% CI, 0.23–1.52]). Conclusions: IDA is a prevalent comorbidity in CVT, affecting predominantly young women with benign, treatable causes of IDA. Although associated with more severe initial findings, long‐term outcomes did not differ from those of patients without IDA. Appropriate recognition and specific management of IDA should be considered in patients with CVT.

25 April 2025 in Revue Neurologique
Verified
Journal Article
Open access
AAA. Aghetti
A. Aghetti
VBV. Bouteloup
V. Bouteloup
JLJ. Lebenberg
J. Lebenberg
MCM. Chupin
M. Chupin
EGE. Gourieux
E. Gourieux
EJE. Jouvent
E. Jouvent
In the elderly, white matter hyperintensities (WMH) are usually rated as periventricular or deep. However, recent data suggest that superficial WMH may be associated with distinct mechanisms and may be associated with milder underlying tissue alterations. We developed and validated a new grading scale to differentiate superficial WMH from other WMH (either periventricular or deep). We evaluated individuals with high loads of WMH from MEMENTO, a multicenter memory-clinic study, to evaluate the links between superficial WMH and 1) MRI markers of cerebral small vessel disease (number of lacunes and microbleeds and normalized brain volume); 2) cognitive outcomes including global evaluation with Mini Mental State Examination (MMSE). Our analytical sample included 208 participants. Participants with higher grades of superficial WMH had larger normalized brain volumes (82.1±1.3% vs 81.0±1.1%, P<0.001) and were more frequently women (85.0% vs 51.4%, P=0.01). In total contrast but as expected, participants with higher grades of other WMH were older (79.8±8.1 vs 75.5±6.2 years, P<0.001), had more often lacunes (41.7% vs 7.1%, P<0.001) and performed worse at the MMSE (26.8±2.0 vs 28.1±1.7, P=0.01). Our results support the hypothesis that superficial WMH are distinct from other WMH and probably correspond to mild tissue alterations.

7 April 2022 in Drugs in Context
Verified
Journal Article
Open access
AAAgnes Aghetti
Agnes Aghetti
PRPeggy Reiner
Peggy Reiner
Anticoagulation therapy is used for the management of atrial fibrillation to prevent new clots from developing. However, neurologists face the challenge of when to initiate/reintroduce treatment after a recent episode of stroke without increasing haemorrhagic risk, especially if the stroke is large and/or complicated with haemorrhagic transformation. This report describes the case of a 72-year-old man who had an ischaemic stroke of the right posterior cerebral artery. The patient had permanent atrial fibrillation, discovered in hospital. He was not on chronic anticoagulation therapy before stroke. His anticoagulation therapy was postponed due to a haemorrhagic lesion, leading to new ischaemic stroke. The patient suddenly had right hemiplegia with aphasia for which a mechanical thrombectomy was performed but complicated by embolization into the left posterior cerebral artery with failure of thromboaspiration of this clot. Finally, the patient presented with intracranial hypertension due to ischaemic lesions and died 3 days after his readmission. When to start anticoagulation therapy after ischaemic stroke is an unresolved question but should be discussed at least twice weekly in a stroke unit based on the clinical evolution of the patient.